Literature DB >> 2559

Comparison between two antibody populations in the EBV system: anti-MA versus neutralizing antibody activity.

A de Schryver, A Rosén, P Gunvén, G Klein.   

Abstract

EBV-neutralizing antibody titers were determined in 11 sera derived from African Burkitt lymphoma or nasopharyngeal carcinoma patients and in the corresponding serum fractions retained above XM 100 Diaflo membranes after low pH treatment, and after recombination of the retained and passed fractions by neutralization of the acidified samples. They were compared with the corresponding antimembrane antigen (MA) titers in seven of the same sera. While all sera tested showed substantial increase of the anti-MA activity in the retained fraction, resulting in a significantly increased mean titer, EBV neutralizing activity did not change at all after identical treatment or changed only in a random fashion, resulting in stable mean titers. It is suggested that anti-MA and neutralizing antibodies are directed against at least partly different antigens on the virus.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 2559     DOI: 10.1002/ijc.2910170103

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Papain solubilization of the Epstein-Barr virus-induced membrane antigen.

Authors:  G R Pearson; L F Qualtiere
Journal:  J Virol       Date:  1978-10       Impact factor: 5.103

2.  Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen.

Authors:  G J Hoffman; S G Lazarowitz; S D Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

3.  Neutralization of lymphocyte immortalization by different strains of Epstein-Barr virus with a murine monoclonal antibody.

Authors:  G Miller; L Heston; G Hoffman
Journal:  Infect Immun       Date:  1982-09       Impact factor: 3.441

4.  Antibody-dependent cellular cytotoxicity (ADCC) against Epstein-Barr virus-determined antigens. III. Reactivity in sera from patients with Burkitt's lymphoma in relation to tumour development.

Authors:  M Jondal; P Gunven
Journal:  Clin Exp Immunol       Date:  1977-07       Impact factor: 4.330

5.  Blocking factors against leucocyte-dependent melanoma antibody in the sera of melanoma patients.

Authors:  E Murray; W H McCarthy; P Hersey
Journal:  Br J Cancer       Date:  1977-07       Impact factor: 7.640

6.  Suppression of in vitro Epstein-Barr virus infection. A new role for adult human T lymphocytes.

Authors:  D A Thorley-Lawson; L Chess; J L Strominger
Journal:  J Exp Med       Date:  1977-08-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.